CRC Research Update — September 13, 2026
Today's colorectal cancer research highlights
Curated CRC research, accessible, accurate, actionable
The CRC Digest
Sunday, September 13, 2026
IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
CRC Research Update
-
REGULATORY
-
REGULATORY
FDA delays decision on zanzalintinib plus Tecentriq for metastatic colorectal cancer until March 2027The FDA has extended its approval decision for Exelixis' oral kinase inhibitor zanzalintinib in combination with Roche's Tecentriq to March 2027 while awaiting updated safety and efficacy data, after the drug missed one primary endpoint measuring overall survival in a subpopulation earlier this year. (Fierce Biotech)
-
TREATMENT
Real-world study of 549 Spanish patients evaluates trifluridine/tipiracil plus bevacizumabA multicenter study across 19 Spanish hospitals evaluated real-world effectiveness and safety of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer after at least two prior treatment regimens. (ESMO Gastrointestinal Oncology)
-
LIVING WITH CRC
Quality of life analysis from phase II VOLFI trial compares chemotherapy regimens in RAS wild-type metastatic diseaseA prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial examined quality of life in patients with RAS wild-type metastatic colorectal cancer treated with mFOLFOXIRI plus panitumumab versus FOLFOXIRI. (European Journal of Cancer)
This week's research reflects ongoing regulatory shifts and real-world validation of treatment strategies in metastatic colorectal cancer.
Get CRC research intelligence delivered weekly, free.
SubscribeCRC Digest
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.
Browse Past Issues · Read our full disclaimer · Manage subscription
Useful? Forward it to a colleague. Many of the topics named here have a live research dossier, trajectory and evidence, at Signal Bureau.
Got this from a colleague? Subscribe here. We only ever add readers who sign themselves up.
Evolution Accelerator, Inc. (dba Evolution Labs) · 3941 Park Dr., Suite 20341, El Dorado Hills, CA 95762
You are receiving this because you subscribed to CRC Digest (self-serve signup)
Unsubscribe: honored promptly, no login required. · Privacy policy · Manage or delete your data